Skip to content
Companies

Reprogram Biosciences

Tumor-injected mRNA that reprograms cancer cells

Raised to date

$5M

of $5M offered across 1 Form D filing

Investors
2
Last filed
May 26, 2026

About

Reprogram Biosciences is a preclinical oncology biotechnology company in San Carlos, California, founded in 2025. It develops mRNA-based therapeutics that reprogram solid-tumor cells in situ, using lipid nanoparticle delivery of gene cocktails injected directly into the tumor to induce antigen-presenting function in the cancer cells themselves. The intent is to turn an immunosuppressive tumor microenvironment into a site of immune activation and drive a systemic antitumor response. The company has raised $6 million in seed capital from Unshackled Ventures, 1517 Fund and Narya.

In vivo reprogramming delivered intratumorally means an off-the-shelf product rather than the patient-specific ex vivo manufacturing that conventional cell therapies require, which the company argues is faster and cheaper to deliver.

Funding

  • OtherFiled May 26, 2026Form D
    $5M/ $5M

Product

CellRecodeX platform

Preclinical oncology therapeutics platform

An AI-driven discovery engine that integrates multiple biological foundation models to identify gene combinations which reprogram tumor cells, paired with lipid-nanoparticle intratumoral delivery of the resulting mRNA therapeutics.

  • AI/ML discovery engine built on biological foundation models
  • MRNA-encoded therapeutic gene cocktails
  • Lipid nanoparticle delivery with precision intratumoral targeting

Built for

Patients with solid tumors, reached through oncology clinicians and pharmaceutical development partners

People on file